Janux Therapeutics (JANX): 10% owner sold ~$178K
Lichter Jay, 10% owner at Janux Therapeutics, sold ~$178K of Janux Therapeutics shares.
- ~$178K
- Approx. value · 3,815 sh @ $46.68
- 7,000
- Holds after · shares reported
- Traded
- Sep 13, 2024
- Filed
- Oct 24, 2024
What stands out in this filing
- The sale was 35.3% of the shares this insider held before it; the filing reports 7,000 shares afterwards.
- 3,815 shares at an average of $46.68 each, as reported on the form.
- No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 13, 2024 · this disclosureInsider10% owner sold ~$178K of JANX shares in the open market
What came next
- Oct 16, 2024Insider · 1 personInsiders: 7 sales (~$10.5M)
- Oct 17, 2024Insider10% owner sold ~$92K of JANX shares in the open market
- Oct 18, 2024Insider · 2 peopleInsiders: 1 purchase (~$53.7M), 9 sales (~$66.9M)
- Oct 28, 2024Insider · 1 personInsiders: 2 sales (~$1.3M)
- Nov 25, 2024Insider · 1 personInsiders: 2 sales (~$1.3M)
- Dec 3, 2024InsiderCEO sold ~$1M of JANX shares in the open market
- Dec 24, 2024InsiderCEO sold ~$1.4M of JANX shares in the open market
- Jan 2, 2025Insider · 1 personInsiders: 5 sales (~$732K)
- Jan 7, 2025InsiderCEO sold ~$300K of JANX shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Janux Therapeutics
OQRO holds no insider, Congress, fund or contract record for Janux Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JANX page.
How this filing works
Explore the data
Common questions
Which Janux Therapeutics (JANX) insider traded, and how much?
Lichter Jay, 10% owner at Janux Therapeutics, sold ~$178K of Janux Therapeutics shares. 3,815 shares at $46.68.
When did it happen, and when was it made public?
Traded: Sep 13, 2024. Filed: Oct 24, 2024. That is 41 days between the two dates.
What stands out in this filing?
The sale was 35.3% of the shares this insider held before it; the filing reports 7,000 shares afterwards. 3,815 shares at an average of $46.68 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
Does this mean JANX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Janux Therapeutics
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 13F-HRFeb 17, 2026
Everything OQRO holds on this company is on its JANX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data